Faculty interviews


 
 
12
Why should one attend EASD 2019?
81
How can new technologies help improve life of people with diabetes?
181
What challenges remain with regards to diabetes education?
 
 
 
12
Have technological advances in insulin delivery and glucose monitoring lowered the burden of hypoglycemia?
260
Other than technological improvements, what other aspects are key to success in reducing the risk of hypoglycemia events?
417
Is there an established link between hypoglycemia and an increased risk of cardiovascular events and mortality?
 
 
 
14
In terms of cardiovascular risk, as a cardiologist, what do you think should the diabetologist be looking for and when should the patient be referred?
61
Does type 2 diabetes cause more harm to the cardiovascular system than type 1 diabetes?
112
What simple things should a non-diabetologist look for when they see a patient with diabetes?
 
 
 
12
What novel diabetes subgroups have been identified and how do these relate to outcomes?
116
Should these diabetes subgroups be treated differently?
162
Is the existence of multiple subtypes of diabetes a debatable subject?
202
Have any novel genetic markers emerged that might aid in diagnosis and management of diabetes?
 
 
 
12
What are the implications of the DUAL VIII trial?
83
What novel oral peptide treatments have emerged for type 2 diabetes in recent years?
158
What new insulin formulations are being investigated? How do these differ from more traditional formulations?
271
The diabetic brain: culprit or victim?
 
 
 
13
What proportion of patients with type 2 diabetes have diabetic neuropathy and how serious a problem is it in real-life?
97
What are some of the most common misconceptions about diabetic neuropathy and what measures are being taken so that it is recognized early and treated adequately?
229
What are some of the current unmet needs in treatment of diabetic neuropathy and how can these be overcome?
 
 
 
12
SGLT2 inhibitors are now a well-established therapy in patients with type 2 diabetes. What is the evidence for their use in patients with type 1 diabetes?
104
Do SGLT2 inhibitors represent the future in type 1 diabetes?
190
Is the risk of ketoacidosis worrisome with the use of SGLT2 inhibitors in type 1 diabetes?
 
 
 
11
What impact does exercise have on vascular health in patients with type 2 diabetes?
124
Can current European guidelines on prevention of diabetes be considered adequate in reducing the burden of disease?
195
Do new glucose lowering drugs have any impact on quality of life?
 
 
 
11
What are the main take home messages from cardiovascular outcomes trials in diabetes?
190
What has been learned from renal outcome studies in diabetes?
196
How should the way we currently treat diabetes change?
 
 
 
11
What are some of the “hot topics” of the 2019 EASD Meeting?
100
What is the importance of the EASD Annual Meeting?
178
What are some of the opportunities offered today by artificial intelligence?
 
 
 
11
What is the Blue Index and how can it help in management of diabetes?
242
What is the current scenario on the use of GLP1-RAs in South Asia?
350
Is continuous glucose monitoring of benefit to patients in a real-world scenario?